Panbela Therapeutics(OTC) PBLA

Market CapN/A

Since IPO (2015)-100%

5 YearN/A

1 Year-100%

1 Month-99%

$0.00

+0.00%

+0.00Today

Panbela Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-09-09

Panbela Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-99%	USD 0.00	2026-09-01
1 month	-99%	USD 0.00	2026-08-10
3 month	+0%	USD 0.00	2026-06-10
Year to date	-99.5%	USD 0.00	2025-12-31
1 year	-100%	USD 0.05	2025-09-08
Since inception	-100%	USD 719,994.24	2015-10-19

Panbela Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$27.91M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

3187.90 (High)

Dividend

$0.00

Beta (Volatility)

3187.90 (High)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $2.50

Estimated Earnings Date

Aug 31, 2026

Dividend

$0.00

Beta (Volatility)

3187.90 (High)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $2.50

Estimated Earnings Date

Aug 31, 2026

PBLA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Panbela Therapeutics

Panbela Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer patients, particularly targeting pancreatic disorders. The company is advancing its flagship drug, SBP-101, through clinical trials aimed at treating metastatic pancreatic ductal adenocarcinoma.

Products and Services

SBP-101: An experimental drug in Phase Ia/Ib trials for pancreatic cancer
Research on treatments for colorectal and ovarian cancers
Focus on addressing pancreatic disorders, including pancreatitis

Growth Outlook

Ongoing clinical trials for SBP-101 may lead to significant market opportunities
Expansion into additional oncology indications could diversify revenue streams
Potential partnerships with larger pharmaceutical companies for development and distribution

Financial Highlights

Q3 2024 net income of -$7.18 million, reflecting ongoing R&D investments
Cash and cash equivalents of $142,000 as of September 30, 2024
Operating expenses of $7.16 million in Q3 2024, primarily for research and development

Panbela Therapeutics, Inc. operates in a highly competitive biotechnology sector, focusing on unmet medical needs in oncology. The company’s commitment to developing therapies for pancreatic cancer positions it uniquely within the market. Despite recent financial challenges, including significant operating losses, the ongoing clinical trials and potential for future partnerships may provide avenues for growth and recovery. Investors may find interest in the company's innovative approach and the potential impact of its therapies on cancer treatment.

AI Generated • Aug 27, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Jennifer K. Simpson, PhD

Website

www.panbela.com

Headquarters

Waconia, MN 55387, US

PBLA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

396.00%

Return on Capital

-10597.93%

Return on Assets

-214.06%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

4.85M

Volume

Avg. Volume

467.714

Financials (TTM)

Gross Profit

-$29.04M

Operating Income

-$36.20M

EBITDA

-$26.40M

Operating Cash Flow

-$15.57M

Capital Expenditure

$0.00

Free Cash Flow

-$15.57M

Cash & ST Invst.

$142.00K

Total Debt

$6.39M

Panbela Therapeutics Performance Analysis

Panbela Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 0	N/A
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A

Panbela Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	N/A
Q1	2024-03-31	N/A
Q2	2024-06-30	N/A
Q3	2024-09-30	N/A

Panbela Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -20,773.68	N/A
2022	2022-12-31	USD -40,748.64	96.2%
2023	2023-12-31	USD -232.43	-99.4%

Panbela Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	99.9%
Q1	2024-03-31	-8251.6%
Q2	2024-06-30	35.5%
Q3	2024-09-30	-0.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$7.17M

+8.7%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$7.17M

+8.4%

EBITDA

-$6.73M

+13.5%

Quarterly Fundamentals

Name

Q3 2024YOY CHG

Total Cash

$142.00K

-84.3%

Total Debt

$6.39M

+23.1%

Accounts Receivable

$332.00K

+114.2%

Inventory

$0.00

N/A

Long Term Debt

$3.19M

-23.8%

Short Term Debt

$3.20M

+220.0%

Return on Assets

-2.14%

N/A

Return on Invested Capital

99.41%

N/A

Free Cash Flow

-$2.12M

+68.2%

Operating Cash Flow

-$2.12M

+68.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ALLRAllarity Therapeutics, Inc.

ALLRAllarity Therapeutics, Inc.$1.25-0.95%

DRMADermata Therapeutics, Inc.

DRMADermata Therapeutics, Inc.$1.20-0.83%

MTVAMetaVia Inc.

MTVAMetaVia Inc.$1.75+0.57%

NUWENuwellis, Inc.

NUWENuwellis, Inc.$0.77-3.94%

PALIPalisade Bio, Inc.

PALIPalisade Bio, Inc.$2.01-1.95%

QNRXQuoin Pharmaceuticals, Ltd.

QNRXQuoin Pharmaceuticals, Ltd.$6.90-1.00%

VRAXVirax Biolabs Group Limited

VRAXVirax Biolabs Group Limited$2.85+4.40%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TNONTenon Medical

TNONTenon Medical$5.30+1.17%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$148.18+0.00%

NVDANvidia

NVDANvidia$218.36-0.02%

INTCIntel

INTCIntel$100.32-0.06%

NUNu Holdings

NUNu Holdings$15.02+0.00%

AAPLApple

AAPLApple$326.57+0.04%

PATHUiPath

PATHUiPath$13.87+0.02%

Questions About PBLA

What is the current price of Panbela Therapeutics?

Panbela Therapeutics is trading at $0.00 per share.

What is the 52-week range for Panbela Therapeutics?

Over the past 52 weeks, Panbela Therapeutics has traded between $0.00 and $2.50.

How much debt does Panbela Therapeutics have?

As of the most recent reporting period, Panbela Therapeutics reported total debt of $6.39M.

How much cash does Panbela Therapeutics have on hand?

Panbela Therapeutics reported $142.00K in cash and cash equivalents in its most recent financial results.

What is Panbela Therapeutics’s dividend yield?

Panbela Therapeutics does not currently have a dividend yield.

Panbela Therapeutics(OTC) PBLA

Panbela Therapeutics Financials at a Glance

PBLA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Panbela Therapeutics

PBLA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Panbela Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PBLA

What is the current price of Panbela Therapeutics?

What is the 52-week range for Panbela Therapeutics?

How much debt does Panbela Therapeutics have?

How much cash does Panbela Therapeutics have on hand?

What is Panbela Therapeutics’s dividend yield?

Premium Investing Services